Skip to main content

Remote Job Finders (RJF)

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C. A similar dynamic is now playing out between Eli Lilly and Novo Nordisk in the obesity space, with some key differences.
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market
Scroll to top